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Abstract: Oncology outcomes research could benefit from the use of an oncology-specific 
electronic medical record (EMR) network. The benefits and challenges of using EMR in 
general health research have been investigated; however, the utility of EMR for oncology out-
comes research has not been explored. Compared to current available oncology databases and 
registries, an oncology-specific EMR could provide comprehensive and accurate information 
on clinical diagnoses, personal and medical histories, planned and actual treatment regimens, 
and post-treatment outcomes, to address research questions from patients, policy makers, the 
pharmaceutical industry, and clinicians/researchers. Specific challenges related to structural 
(eg, interoperability, data format/entry), clinical (eg, maintenance and continuity of records, 
variety of coding schemes), and research-related (eg, missing data, generalizability, privacy) 
issues must be addressed when building an oncology-specific EMR system. Researchers should 
engage with medical professional groups to guide development of EMR systems that would 
ultimately help improve the quality of cancer care through oncology outcomes research.
Keywords: medical informatics, health care, policy, outcomes
Introduction
The term “EMR” generally refers to an electronic medical record and can indicate 
the establishment and use of standardized electronic databases for health care, with 
a digital record as its basis. Current EMR systems contain a record of all clinical, 
administrative, and laboratory encounters between a patient and a provider, including 
medical notes, results, billing claims, and insurance information, typically linked 
with a unique patient identifier (Figure 1). The most comprehensive EMR databases 
would be those that have a stable population (eg, low rate of patients moving out of 
the medical system) and include records from all in- and out-patient care, laboratory 
and radiological results, and all prescribed and over-the-counter (OTC) medica-
tions, with a unique identifier for each patient to link them to different medical care 
providers and services, and to maintain confidentiality.
Current EMR systems in the United States (US) that fit this description exist at a 
few large, integrated health providers, such as Kaiser Permanente, Harvard Pilgrim 
Health System, and the Department of Veterans Affairs (VA), but are generally lacking. 
With only 25% of Americans belonging to any type of health maintenance organiza-
tion (HMO),1 this type of health care structure is not typical. While European and 
socialized countries may have existing platforms (eg, registries, health care systems) 
that are more readily suitable to EMR, with some exploring EMRs in oncology,2 
the primary focus of the current article is on the US.ClinicoEconomics and Outcomes Research 2010:2 
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The potential utility of EMR to enhance clinical medicine 
was recognized in the 1990s, primarily due to the increasing 
use of the Internet. The widespread use of the Internet 
fostered more cooperative relationships among doctors, 
patients, and other care providers, allowing for merging of 
data across different treatment settings. Several government 
initiatives and programs have been developed over the past 
several years to increase the use and development of EMR 
systems in the US (Table 1).
The use of an EMR in clinical medicine offers numerous 
potential benefits, including an improvement in the quality 
of patient care, a reduction in the cost of health care, and 
improvement in the ease of transferring patient information 
among providers.3 In the US, maintenance of electronic 
records of continuous care is often hindered by frequent 
changes in providers and plan members, due to job changes 
or changes in coverage, but EMR adoption across a wide 
range of health systems could potentially provide a seamless 
record even across such changes and patient migration. The 
adoption of EMR, however, has generally been slow due to 
the cost of system implementation and user training. While 
the US government has been promoting the adoption of a 
national EMR system, little guidance has been provided on 
how it should look or function.4 To date, less than 20% of 
group physician practices in the US have adopted EMRs.5 
In particular, small practices, which make up approximately 
80% of all physician practices, have been slower to adopt 
EMR than physician groups associated with larger hospitals 
and health systems.6 The general challenges of adopting and 
using EMR have been discussed elsewhere.3,7
While the benefits and challenges for adoption and use 
of EMR in clinical medicine and general health research 
have been investigated, the utility of EMR for oncology 
outcomes research has not been explored. In this paper, 
we describe how oncology outcomes research can benefit 
from the use of a hypothetical oncology-specific EMR net-
work that incorporates widespread coverage, both across 
provider types and networks, as well as geographically. 
Although this level of coverage may not currently exist, even 
in best practice, among existing EMR systems, the purpose 
of this paper is to demonstrate the breadth of research ques-
tions and beneficial parties who will be affected when and if 
such a system is implemented. In addition, we describe the 
specific challenges that must be addressed when building 
such a system.
EMR for oncology research
With comprehensive and accurate information on clinical 
diagnoses, personal and medical histories, planned and 
actual treatment regimens, and post-treatment outcomes, 
EMR systems could provide a wealth of data for outcomes 
research. In a comprehensive literature review of the number 
and types of EMR systems used for outcomes research from 
2000 through 2006, the number of EMR-based research 
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Figure  schematic of current electronic medical record (EMR) components.ClinicoEconomics and Outcomes Research 2010:2 
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studies conducted annually has increased 6-fold.8 Although 
the use of computerized clinical information has been 
demonstrated to improve the efficiency of oncology clinical 
practice (eg, with computerized chemotherapy producing 
significantly fewer errors than manual prescriptions,9 only 
10% of 126 published studies of outcomes research using 
EMR from the US focus on oncology outcomes.8 In addition, 
several limitations exist in using EMR data, which must 
be considered (discussed later).
Implementation of comprehensive EMR systems that 
focus specifically on the treatment of oncology patients 
could answer many questions that are unique to oncology 
clinical practice (eg, see Table 2). The relevance of research 
from such a resource would be broad, with the potential to 
benefit parties at each level within the US health care struc-
ture from oncology patients, researchers, and clinicians; to 
policy makers, health economists, and administrators; to 
pharmaceutical and other health companies. These various 
perspectives are described in more detail below (see also 
Figure 2).
Utility of oncology EMR compared 
to other available data sources
Several clinical and research databases are currently being 
used to conduct clinical outcomes research in oncology. 
Table 3 provides a summary of some of these data sources 
and their advantages and disadvantages when conducting 
outcome research, and how an “ideal” EMR could improve 
upon such databases. These data sets vary in breadth of 
coverage (national to regional), funding source (private to 
national government funded), mechanism of data collection 
(continuous, post hoc), and scope of data collected. While 
each contains unique elements that allow it to answer specific 
oncology research questions among certain populations, each 
is also limited by specific constraints that may be improved 
upon by a widespread, comprehensive, and provider/
insurance-neutral EMR network of oncology practices.
An ideal oncology EMR would provide several advan-
tages over current research, observational studies, and claims 
databases. Clinical data gathered in the course of routine 
medical care, if systematically collected and routinely stored, 
would provide a data source less costly in labor and opera-
tional funding than current research databases; would be more 
accessible than integrative HMO data; would prospectively 
collect patient data and characteristics, permitting analyses 
of factors from many points during the course of disease both 
pre- and post-diagnosis (unlike most population-based case-
control studies); and would follow the entire patient cancer 
experience from diagnosis onward, collecting information 
that may affect outcomes. Further, this information would 
Table  Brief history of government initiatives to develop and use EMR
Date Government entity Initiative Description
2004 President Bush Establishment of the position of 
National Health Coordinator for 
information Technology (ONC)41
Position was charged with coordinating federal and private-sector 
health information initiatives to achieve the widespread adoption of 
intra- and interoperable electronic health records within 10 years
2004 FDA Critical Path initiative42 Designed to stimulate and facilitate a national effort to modernize the 
scientific process of moving a drug or device through discovery into a 
medical product
May 2008 FDA sentinel initiative43 Creation and implementation of the sentinel system, a national, 
integrated, electronic system of existing data sources that will be 
maintained separately by their owners, with strong privacy and security 
safeguards, can be queried to monitor the performance of a product 
throughout its life cycle
2006 CMs strategic plan for 2006 to 200944 Written that secure electronic records and electronic prescriptions 
(collectively, EHRs) would promote reliable and affordable health care, 
streamline billing and delivery of health care to patients, increase the 
ability of diverse EMR systems to work together (eg, interoperability), 
decrease transcription and other errors, and promote education of 
patients and care providers
2009 
 
President Obama 
 
American Recovery and  
Reinvestment Act of 2009  
(“the stimulus Package”)4
includes the Health information Technology Extension Program with 
$19 billion in grants and loans set aside for infrastructure, and incentive 
payments for providers who adopt certified EHR technology
Abbreviations: CMs, Center for Medicare and Medicaid services; EHR, electronic health record; EMR, electronic medical record; FDA, Food and Drug Administration; 
ONC, Office of the National Coordinator.ClinicoEconomics and Outcomes Research 2010:2 
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be more suitable for real-world research than data obtained 
in clinical trials.
Relevance to the patient, clinician, 
and medical researcher
For patients, providers, and researchers, the most relevant 
questions focus on improving health and quality of life 
(QOL), providing better quality of care, and advancing dis-
ease knowledge. For example, an oncology patient would be 
interested in their chances of surviving existing disease and 
preventing future tumor recurrence. While many population-
based observational studies have examined the relation of 
pre-diagnosis lifestyle factors – such as weight, diet, exercise, 
nonsteroidal anti-inflammatory drug (NSAID) use, alcohol 
consumption, and smoking – with cancer risk, the effect of 
risk factors on survival after diagnosis has been more difficult 
to study. In particular, studies that attempt to elicit self-
reported risk factors occurring after diagnosis are susceptible 
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to lead-time bias and recall bias,10 particularly if the time 
between diagnosis and interview is protracted, and only 
certain individuals survive long enough to be interviewed. 
Further, because the experience of cancer treatment, as well 
as the presence of disease itself, can affect behaviors, pre-
diagnosis risk-factor information may not accurately reflect 
behaviors after diagnosis. An EMR system that collects 
information on some common health-related behaviors 
both pre- and post-diagnosis, medications and treatments, 
and response to treatment in a standardized fashion could 
aid in elucidating the complex inter-relationships among 
these factors. In addition, patient choice – such as the type 
of therapy or the decision to treat their disease at all – is a 
primary predictor of treatment patterns in several cancers,11–15 
and information collected by EMR on treatment efficacy 
and side effects may directly influence the decision-making 
process.
A practicing oncologist might be interested in studies of 
various chemotherapeutic agents, dosages, and regimens to 
prolong patient survival with the least risk of toxicity, side 
effects, and other detriments to QOL. Although clinical trial 
data provide some evidence of efficacy, they are conducted 
within a controlled treatment structure and among patients 
that are highly selected by health status, tumor type, and 
previous response to treatment. Thus, the data from these 
trials may not provide a realistic view of treatment response 
within a “real-world” administration. In addition to wide 
variation among cancer patients with respect to personal and 
tumor characteristics, differences in psychological factors 
and lifestyle choices may influence their course of disease 
and response to treatment. Even among patients with similar 
prescribed regimens and dosages, individual adherence to 
recommended treatment, and differences in patient choices 
of treatment type, may further influence response.
In an EMR-based oncology practice, the adherence to 
prescribed regimen, reported treatment side effects, psycho-
logical concerns, and possibly other modifiers of treatment 
efficacy would be recorded with each clinic visit. In combina-
tion with quantifiable outcomes data (eg, disease progression 
or survival), an oncology EMR can provide clinicians with 
a more representative data source by which to develop their 
medical recommendations. These data from an EMR could 
also help researchers investigate ways to improve guideline 
adherence and implementation of evidence-based medicine 
for follow up and treatment that may improve the care 
received by the oncology patient.
Advances in biotechnology and bioinformatics have per-
mitted the examination of etiologic and outcomes research 
in oncology with increasing detail, with molecular, cellular, 
and other biological measurement often incorporated to char-
acterize cancer and disease progression (see Table 2). EMR 
systems that record such biomarker data, when available, over 
the course of clinical practice could provide a potentially cost-
effective16 and efficient means for conducting this research, 
and are a valuable tool in pharmacoepidemiologic studies.
Relevance to the policy maker
From the policy makers’ perspective, outcomes research 
in oncology can provide clues to identify deficits in out-
reach and programmatic spending and current health care 
resource utilization and accessibility. The recent Institute of 
Medicine (IOM) report on optimizing the effectiveness of 
health care services17 recommends conducting systematic 
reviews of current published research on the effectiveness of 
health services to create a link between scientific evidence 
and clinical decision-making. New research studies using 
comparative effectiveness study methods (eg, comparing 
new drugs, devices, and procedures to current treatment 
options)18,19 can also provide answers on what treatments are 
most effective from both the cost and clinical standpoints for 
specific populations, such as addressing whether health care 
resources are being spent on the most effective treatments 
for oncology patients. EMR systems could be a valuable 
resource for conducting these research studies in oncology, 
because they contain more comprehensive health histories 
and outcome information than claims databases or other 
disease registries for researchers to address a variety of treat-
ments and outcomes.
Research and public health measures aimed at identifying 
deficits and disparities in medically underserved groups, and 
mitigating these differences, have become high priorities of 
government health care program policies.20–23 Rates of  cancer 
incidence, mortality, and survival may differ by age, race/
ethnicity, socioeconomic status (SES), educational attainment 
level, and geographic location,24 and it is thought that access 
to health care, screening, and treatment resources, and the 
quality of treatment given, may underlie a large proportion 
of these differences.25 For example, analyses of a population-
based cancer registry of patients aged 66 to 85 years with 
a primary diagnosis of colorectal, breast, lung, or prostate 
cancer during 1992 to 2002, researchers found that black 
patients were significantly less likely than white patients to 
receive therapy for their cancer, and there was no evidence 
that the magnitude of racial disparities had lessened during 
the study period.26 Disparities in cancer treatment can vary 
across cancer types, with differential impacts on access to ClinicoEconomics and Outcomes Research 2010:2 0
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care, ability to absorb costs, and cultural and personal biases, 
all of which are factors not currently captured in most avail-
able data. EMR systems that contain detailed insurance, 
personal, and clinical information may form a more complete 
picture of the many factors that influence treatment patterns, 
providing policy makers with better direction when directing 
health care policies.
Relevance to the pharmaceutical 
industry/manufacturer
EMR systems could provide answers to research questions 
relevant to several groups within the pharmaceutical and 
biotechnology industries. With comprehensive and accurate 
information on various aspects of patient-care information, 
EMR could potentially provide a set of clinical data to 
answer questions related to marketing, outcomes research, 
research and development, and phase IV post-marketing 
surveillance (eg, adverse events identification, targeted 
evaluation of treatment groups, observational studies), among 
others. For example, information in EMR (received by the 
pharmaceutical industry data de-identified of personal infor-
mation) could be mined to determine the size of therapeutic 
markets for rare cancers or conditions, or in populations 
that are resistant to or cannot take conventional medication. 
EMR could also aid industry in evaluating the prevalence or 
incidence of certain conditions and associated co-morbidities, 
in various subpopulations, in certain types of hospitals, or in 
different areas, to aid in marketing drugs and supporting new 
drug applications and other regulatory documentation.
Economic analyses and health care resource use evalu-
ations would also be possible with EMR systems. Cost-
effectiveness strategies of pharmacologic therapy could be 
evaluated, including for example, population of predictive 
health economics models for forecasting costs and market 
share. Forecasting models could also be developed from 
these data, with particular focus on specific drugs, disease 
stage, line of therapy, or clinic type, provided that issues 
of generalizability were accounted for (see later section). 
From a marketing point of view, EMRs could also be used 
to develop differentiation strategies among competing firms 
by evaluating patient profiles and drug use.
Because EMRs represent a “real-world” patient cohort, 
these data could also be used to aid in preparation of regu-
latory applications using actual population-based data, as 
well as in identification of possible safety issues, and could 
therefore also be of use in pharmacovigilance studies. A clear 
EMR record of all medications prescribed and taken, whether 
for medications, biological products, or herbal supplements 
could aid in understanding and preventing adverse events 
with certain therapeutics. EMRs may be beneficial for 
process-of-care studies, where insight into patient care, dis-
ease endpoints, and therapies could be evaluated in tandem 
in a single EMR and could aid in beneficial results for 
patients (eg, shorter lengths of stay in hospital, preventive 
or palliative care). Detailed clinical and laboratory history of 
patients undergoing treatment contained in EMR may reveal 
new indications or contraindications of existing therapeutics. 
Effectiveness of therapeutics could also be tracked in certain 
situations through clinical practice and reporting of patient 
outcomes.
Challenges of using EMR 
for oncology research
Despite the promise that EMR can provide for oncology 
outcomes research, several challenges must be considered 
to develop a comprehensive, valid, and useful data resource. 
While many of these challenges of EMR are general, some 
are oncology specific. Challenges can include structural,27,28 
clinical,29,30 and public health research-related issues,31,32 all of 
which should be considered in building a useful EMR system.
structure
At present, a variety of options are available in EMR systems, 
and physician groups and health systems are free to choose the 
system best suited to their needs.3 For example, the American 
Society of Clinical Oncology (ASCO) has developed a set 
of recommendations for oncologists to use in choosing an 
EMR.33 ASCO identified several important elements that 
should be included in any EMR used by an oncologist: 
ability to enter staging information, work flow, chemotherapy 
doses and administration, toxicity assessment, clinical trial 
management, drug inventory management, and survivor care.
interoperability
Regardless of the type of EMR system chosen, it will need 
to be interoperable, that is, having the ability to interact and 
exchange data across departments and clinics (eg, laboratory, 
pathology, clinic).34 Without interoperable interfaces, infor-
mation cannot be exchanged easily, which can affect the work 
flow for the clinic and could lead to missing information 
within the medical record and major problems with data 
quality and completeness.
incorporation of different data formats
Information available in an EMR may include a variety of 
data formats, ranging from text for office visits to images ClinicoEconomics and Outcomes Research 2010:2 
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from radiology visits. In addition, results can include text 
reports, numerical data such as laboratory values, graphs, 
and images such as CT scans or MRIs. As such, the results 
can be entered using a wide variety of methods, including 
direct data uploads from the processing laboratory, scan-
ning of text using optical character recognition, or simply 
capturing the electronic readout as an image. Physician 
orders can be recorded in several ways, with varying degrees 
of automation, including selecting individual chemotherapy 
drugs with pre-populated fields or customizing automated 
orders with free-text entry. However, treatment offered out-
side the institutions that contribute to the EMR (eg, radiation 
therapy) may be available only from information scanned 
into the EMR system, which may not be readily searchable 
by computer algorithms if they contain non-text fields such 
as images.
Due to the variety of sources, data collection may be time 
intensive, requiring manpower and database management.35 
Because some of the information in the EMR may be text 
based,27 rather than consisting of a data set or collection of 
raw values, natural language algorithms may be necessary 
to extract the information of interest. Studies using natural 
language algorithms have been able to identify a majority of 
potential study participants by disease type. For example, a 
study designed to identify cases of heart failure from an EMR 
found 100% sensitivity and 97.8% specificity when using 
this method.36 Other limitations may include not being able 
to extract information from reports that have been scanned 
into the medical record using these algorithms, and not 
having access to previous paper records that have not been 
incorporated into the EMR.3
Clinical
variety of diagnostic coding vocabulary
The coding vocabulary used to identify and define cancer 
cases within the medical record varies by physician type. 
Standard codes include the American Joint Committee 
on Cancer (AJCC) codes for tumor staging, Systematized 
Nomenclature of Medicine (SNOMED) used primarily by 
pathologists, and various International Classification of 
Diseases (ICD) codes (ICD-9-CM, ICD-10, and ICD-O), 
and Current Procedural Terminology (CPT) for coding of 
diagnoses and procedures performed during diagnosis and 
treatment. In some cases, the clinicians are not the ones 
directly recording the codes, but they provide a narrative 
of the disease history or clinic visit that is subsequently 
coded by medical record coders at a later time, strictly for 
billing purposes. Disease progression of cancer, in particular 
metastasis or recurrence, may follow a variety of pathways, 
and there is no standard for recording progression in the 
medical record, nor are cancer-specific codes available for 
identifying cancers that have progressed. Because several 
standardized codes are used over the course of an oncology 
patient’s care by different departments and treating physi-
cians, with some used primarily for billing purposes, the 
researcher will need to consider all sources of codes, and 
possibly lack of codes, to identify cancer cases or they may 
miss identifying all cases of a particular cancer.
Linking of departments and continuity of care
Cancer, as a diagnosis, encompasses a variety of tumor types 
that are treated by physicians in a variety of specialties, 
including general surgery, hematology, oncology, urology, 
and endocrinology. Within a comprehensive health care 
system, these specialties may be handled with an inter-
connected EMR; however, outside these health systems, 
the specialties may not be linked in a standardized fash-
ion, or some specialty department may not use EMR. In 
addition, practices are often challenged in the amount of 
retrospective information that they receive from prior health 
care providers and institutions, and are also constrained by 
costs and logistics in the amount of data they can enter into 
the EMR due to inadequate time and staffing. Longitudinal 
observations of study subjects may be difficult if data prior 
to the adoption of the EMR have not been added to the 
database. The concerns of not incorporating records from 
all specialties providing care are 2-fold.
First, patients with some cancers, such as prostate cancer 
or early-stage breast cancer, may be diagnosed and treated 
primarily within one or two departments (eg, urology, 
surgery) or, as is the case for the majority of patients, different 
outpatient clinics entirely. If the EMR does not link these 
departments, these patients and essential elements of their 
clinical history may be missed. This may also make the 
construction of the oncology patient’s cancer experience 
incomplete. Similarly, for childhood cancers, specialized 
hospitals and clinics that deal primarily with pediatric cancers 
may or may not be connected with the EMR where the chil-
dren receive their primary care. For researchers interested in 
other subpopulations, such as those investigating rare cancers 
or conditions that are difficult to diagnose in some cases 
(eg, Ewing’s sarcoma), the low adoption rates of EMR may 
present a barrier to identifying these small groups, because 
the number of cases may be too small from available EMR 
data, thereby preventing a study from being adequately 
powered for research.ClinicoEconomics and Outcomes Research 2010:2 
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Second, outcomes of procedures that are not considered 
clinically relevant to a particular department may not be 
captured in their EMR system. For example, persisting 
post-surgery incision pain that affects QOL may not be 
recorded within a surgical department EMR as an outcome 
of surgery, particularly if there is a long lag time after the 
procedure or if the patient seeks care from their primary 
care physician.
Research-specific
The most obvious problem with using EMR systems for 
research is that they collect information and are designed for 
the care of each individual patient; the data are not collected 
specifically for research. For example, demographic data 
collected for patient care, rather than research purposes, 
may not be collected systematically with standardized 
definitions. Thus, the rigors of data collection for research, 
including validation, quality checking, and reproducibility, 
are not inherent in the EMR-collected data. Issues related 
to the reliability and validity of a study, such as dealing 
with missing data and generalizability to the source popu-
lation, as well as ethics and privacy concerns and general 
accessibility when using an EMR, must be considered.
Missing data
Missing information in the EMR may lead to misclassifica-
tion of exposure and/or outcome in epidemiologic and other 
research.31 Another consideration is the extent of the data 
collected within the EMR (eg, personal/medical histories, 
planned versus actual treatment regimens, psychosocial 
parameters, follow-up on treatment outcomes). Because 
various physicians or practices may record information 
differently, the researcher will have to make decisions on 
whether the collected data set is complete. A study performed 
in a network of primary-care clinics determined that clini-
cians reported missing clinical information in almost 14% 
of visits.37 In addition, there may be a lag time between the 
clinic visit and data entry into the EMR. The researcher will 
also need to distinguish whether information is missing or 
was just never followed through or recorded. For example, 
the researcher may need to determine whether a record is 
requesting a treatment or recording that treatment was given. 
Insurance claims data sets capture treatments that are given; 
thus, an EMR linked to an insurance claims database could 
help ascertain the difference. If paper records are available, 
they could also be used to identify missing data. Researchers 
will need to account for missing data in their analyses to 
ensure robustness and accuracy.
Generalizability
The population covered within an EMR may not be 
representative of the underlying population in the region, 
thus limiting the generalizability of potential research 
studies to larger populations or to the US in general.31 Due 
to the low adoption rates of EMR mentioned previously, 
there may be few clinics or hospitals in a geographic area 
that collect medical records electronically. Clinics and 
hospitals that have adopted EMR may be different in terms 
of the patient population that uses the facilities compared 
to those clinics and hospitals that have not adopted EMR. 
Even within clinics, there may be differences in patient 
participation and enrollment, depending on physician and 
patient preference, thereby possibly skewing the population 
characteristics. Researchers should keep generalizability 
in mind when interpreting the results of studies conducted 
with EMR data.
Ethical and privacy concerns
Any large database of identifiable personal health information 
(PHI), such as that from an EMR, is subject to the Common 
Rule38 and the Health Insurance Portability and Accountabil-
ity Act (HIPAA), which also has a privacy rule embedded 
within it.39 The researcher must work with the Institutional 
Review Board (IRB) associated with the EMR to ensure that 
the research activity protects the privacy and confidentiality 
of the patients included. Additional safeguards to protect 
the privacy and confidentiality of subject data can include 
de-identification of PHI, password protection, data encryp-
tion, and use of firewalls if there is potential for Internet 
access to the information.40
Conclusions and future directions
Cancer continues to be a leading cause of morbidity and 
mortality, and there is an increasing need for new data 
sources to address questions regarding oncology outcomes, 
particularly when current data systems used in research 
are limited. The drive to achieve a nationwide system of 
electronic medical records, and the recommendation by 
the IOM to optimize health services through systematic 
reviews is a call for researchers to engage with medical 
professional groups to help guide development of EMRs 
and EMR-based systems that have utility for several groups, 
including patients and policy makers. This interaction will 
ensure that secondary uses of the data are secure and protect 
patient privacy, are useful to researchers and others, and will 
help improve the quality of cancer care through oncology 
outcomes research.ClinicoEconomics and Outcomes Research 2010:2 
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